vildagliptin (Galvus)

Expected October 2006 Indications: - diabetes mellitus type 2 - has been used effectively in combination with: - insulin, metformin Dosage: 50 mg PO BID Pharmacokinetics: - metabolized by the liver Adverse effects: 1) GI: nausea/vomiting, diarrhea, abdominal pain, dyspepsia 2) hypoglycemia < 1% 3) edema 2.5% Mechanism of action: 1) dipeptidyl peptidase-4 inhibitor 2) inhibits incretin catabolism 3) enhances incretin system 4) improves lipid profile

Interactions

drug interactions drug adverse effects (more general classes)

References

- Prescriber's Letter 12(9): 2005 Investigational Medicines for Diabetes: Sitagliptan (Januvia) and Vildagliptan (Galvus) Detail-Document#: 220715 (subscription needed) http://www.prescribersletter.com